T ranscatheter aortic valve replacement (TAVR) is the standard of care for inoperable or high-risk surgical patients with severe aortic stenosis (AS) [1] [2] [3] and an alternative to surgical aortic valve replacement in intermediate-risk patients. 4, 5 After the US Food and Drug Administration approval for this procedure, the Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry was developed to capture data on all patients in the United States undergoing commercial TAVR procedures to have an accurate assessment of enrollment and outcomes of this approach in the broadest possible population. 6, 7 Diabetes mellitus (DM) is a widely recognized risk factor for both morbidity and mortality in cardiac valve surgery and coronary angioplasty. 8, 9 Consequently, the nature and magnitude of increased risk conferred by DM in emerging procedures that combine these disciplines, such as TAVR, is potentially a critical Background-Diabetes mellitus (DM) adversely affects morbidity and mortality for cardiovascular diseases and procedures.
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factor in clinical decision making. Unfortunately, current publications on the effect of DM on TAVR-associated morbidity are limited by small sample size and contradictory results. [10] [11] [12] [13] [14] Data on the effect of subgroups of diabetics (eg, insulin treated [IT]) on the prognosis after TAVR are also scarce. 10, 15 Surprisingly, in a recent substudy of the PARTNER trial (Placement of Aortic Transcatheter Valve Trial), 1-year mortality was higher in patients without DM compared with patients with DM, although multivariable analysis was not performed. 16 In the current study, we sought to establish the magnitude of risk and the incremental influence of insulin dependency by examining short-and longterm adverse outcomes according to DM status and therapy in the world's largest TAVR registry.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Design, Setting, and Participants

STS/American College of Cardiology TVT Registry
The TVT Registry is a collaborative clinical registry program developed by the STS and the American College of Cardiology and aims to collect data on all patients undergoing TAVR with a commercially approved device in the United States. 6, 7 Participating centers use standardized definitions to collect clinical information on consecutive TAVR cases including patient demographics, comorbidities, functional status, quality-of-life indices, and procedural details and outcomes. 6, 17, 18 The Chesapeake Central Institutional Review Board and the Duke University School of Medicine Institutional Review Board approved the registry. Both Institutional Review Board committees granted a waiver of informed consent and authorization for this study. Annual data quality checks are implemented at the National Cardiovascular Data Registry data warehouse and the Duke Clinical Research Institute analysis center, including data quality feedback reports and data range and consistency checks.
Study Cohort
The diagnosis of DM was determined by the enrolling sites based on the standard American Diabetes Association criteria. 19 Diabetic patients were further subcategorized according to DM therapy into IT and non-IT subgroups. TVT Registry clinical records for procedures performed from November 2011 through September 2015 were linked to Medicare administrative claims using direct patient identifiers (name and social security number) by the Centers for Medicare & Medicaid Services (CMS). Per the CMS National Coverage Determination, all patients had echocardiographic documentation of severe AS and an assessment by 2 cardiothoracic surgeons who independently deemed the patients as at high or prohibitive surgical risk of mortality from surgical aortic valve replacement. Of the 47 643 index TVT procedure records, 14 824 were not linked to Medicare, either because of patient nonparticipation in the Medicare parts A and B fee-for-service program at the time of the index procedure or an inability to link the index admission to a Medicare inpatient claim.
Study Outcomes
Primary outcomes studied included mortality, stroke, rehospitalization because of heart failure, new dialysis, and myocardial infarction (MI) at 30 days and 1 year. In-hospital outcomes were collected from the TVT Registry, and both stroke and reoperation outcomes were adjudicated by a board-certified cardiologist using Valve Academic Research Consortium definitions. 17, 18 This process involved review of specific site queries and deidentified source records as needed. After hospital discharge, death was identified using the Medicare Denominator file. Patient follow-up was considered to be censored at the end of the follow-up period (October 1, 2015). Medicare inhospital administrative claims files were used for detection of rehospitalization events during the study interval using the following 
Statistical Analysis
Baseline characteristics and in-hospital outcomes of the study population were presented according to DM status. Categorical variables were summarized as counts and percentages and compared using the Pearson χ 2 test or Fisher exact test. Continuous variables were summarized as medians with interquartile ranges and compared using the Wilcoxon rank-sum test. Unadjusted and adjusted associations between DM and in-hospital mortality were assessed using the logistic regression models. Covariates in the multivariable model were selected on the basis of a validated TAVR in-hospital mortality risk model 20 ( Table I in the Data Supplement). Clustering of patients within hospitals was taken into account using the generalized estimating equation method with an exchangeable working correlation structure.
Cumulative incidences of adverse clinical outcomes at 30 days and 1 year after TAVR were compared between patients with and without DM using Gray method. For nonfatal outcomes, death was considered as a competing risk. Because the cumulative incidence curves for mortality cross each other, 1-year mortality was compared between patients with and without DM using a pointwise test based on the complementary log-log transformation. 21 Unadjusted and adjusted associations of DM with 1-year mortality were assessed using the Cox models. The assumption of proportional hazards for DM was checked using graphs and tests. Because of violation of this assumption, an interaction term between DM and time was added to assess the time-dependent association between DM and mortality. A robust sandwich variancecovariance estimator was used to account for clustering of patients within hospitals. The covariates in Table I in the Data Supplement were included for adjustment. To further assess the effect of glomerular filtration rate (GFR) on the association between DM and 1-year mortality, additional interaction terms between GFR categories (<30 versus 30-60 versus >60 mL min −1 1.73 m − 2) and DM were added to the Cox regression models. An additional landmark analysis for mortality with
WHAT IS KNOWN
• Diabetes mellitus is a widely recognized risk factor for both morbidity and mortality in cardiovascular disease and procedures.
• Assessment of predictors of increased short-and long-term mortality and complications from transcatheter aortic valve replacement databases, registries, and clinical trials has suggested a link between diabetes mellitus and adverse clinical outcomes after transcatheter aortic valve replacement yet the data are inconclusive.
WHAT THE STUDY ADDS
• Diabetes mellitus is not associated with increased risk of short-term mortality or major complications except for acute kidney injury after transcatheter aortic valve replacement.
• Adjusted 1-year mortality is increased in diabetics after transcatheter aortic valve replacement, and this is driven mainly by increased mortality among patients with insulin-treated diabetes mellitus. TAVR in Diabetic Patients restart of the follow-up period after discharge from TAVR was also performed using similar methods and multivariable adjustments.
A separate multivariable Cox proportional hazards model was constructed to identify factors associated with 1-year mortality in DM patients after TAVR. A univariable analysis was performed first on the adjustment variables, and those with a P value ≤ 0.2 were included in the Cox model. All independent variables had a missingness rate of <2%, so single imputation was used, that is, missing data were imputed to the median for continuous variables and to the mode for categorical variables. All analyses were performed using SAS software, version 9.4 (SAS Institute Inc, Cary, NC), and a 2-sided P value <0.05 was considered statistically significant. 
Results
Study Cohort
In-Hospital Outcomes
In-hospital mortality data were available in 47 635 of 47 643 patients (99.98%). In-hospital mortality was 4.3% in nondiabetics Table 2 ). Patients with IT DM had 4.4% in-hospital mortality, and non-IT patients had 3.3% (P<0.001). Diabetics were also found to have lower rates of in-hospital major bleeding and atrial fibrillation and higher rates of acute kidney injury stage 3 and new dialysis ( Table 2) . Length of stay in the intensive care unit and in the hospital was higher among patients with DM. Postprocedural echocardiographic characteristics are shown in Table III in the Data Supplement. A multivariable analysis of the association of DM status and DM therapy with in-hospital mortality is presented in Table 3 . Overall, adjusted odds of in-hospital mortality was similar between patients with and without DM (odds ratio, 0.94; 95% confidence interval [CI], 0.84-1.04; P=0.218). Patients with non-IT DM had significantly lower in-hospital mortality (odds ratio, 0.84; 95% CI, 0.74-0.95; P=0.007), and patients with IT DM had a nonsignificant increase in in-hospital mortality (odds ratio, 1.13; 95% CI, 0.99-1.31; P=0.078), compared with patients without DM.
Thirty-Day and 1-Year Outcomes
Thirty-day and 1-year outcomes were assessed in 32 820 CMS linked patients out of 47 643 patients (68.9%). At 30 days, patients with DM had lower mortality (5.0% versus 5.9%; P<0.001), increased heart failure readmission rates (4.7% versus 3.7%; P<0.001), and higher rates of new dialysis (2.5% versus 1.6%; P<0.001), compared with those without DM (Table IV in the Data Supplement). Thirty-day mortality according to DM therapy was 5.9%, 6.1%, and 4.4% in patients with no DM, IT DM, and non-IT DM, respectively (P<0.001 for IT DM versus non-IT DM and versus no DM). Thirty-day heart failure readmission, MI, and new dialysis were higher in the IT DM group (P<0.05 for all compared with no DM and to non-IT DM, Table 4 ). Stroke rates at 30 days were similar between groups.
At 1 year, patients with DM had similar mortality (21.8% versus 21.2%; P=0.274), increased cumulative incidence of heart failure readmissions (17.0% versus 12.8%; P<0.001), MI (2.7% versus 1.8%; P<0.001), and increased need for new dialysis (4.0% versus 2.4%; P<0.001; Table IV in the Data Supplement). One-year mortality according to DM therapy was 21.2%, 24.8%, and 20.1% in patients with no DM, IT DM, and non-IT DM, respectively (P<0.001; Figure 1 ). In a landmark analysis, examining events after discharge post-TAVR, patients with DM had increased postdischarge 1-year mortality (18.9% versus 17.8%; P=0.039). Similarly, postdischarge 1-year mortality according to DM therapy was 17.8%, 21.8%, and 17.4% in patients with no DM, IT DM, and non-IT DM, respectively (P<0.001). Cumulative incidence of mortality according to the specific DM therapy is shown in Figure I in the Data Supplement. One-year heart failure readmission, MI, 
Baseline Factors Associated With Increased 1-Year Mortality in Diabetics
The following baseline parameters were identified in DM patients undergoing TAVR as independent predictors for 1-year all-cause mortality: IT DM, older age, lower body surface area, lower left ventricular ejection fraction, lower hemoglobin, thrombocytopenia and thrombocytosis, procedural date (earlier date associated with increased risk), decreased GFR, dialysis, peripheral artery disease, smoker, New York Heart Association class IV, atrial fibrillation or flutter, severe chronic lung disease or home oxygen, nonfemoral access, moderate/severe mitral insufficiency, nonelective procedure, and lower mean aortic valve gradient (Figure 3) .
Effect of Renal Function on the Associations of DM Status and Therapy With 1-Year Mortality
The effect of GFR on the association between DM and 1-year mortality according to 3 GFR categories (<30 versus 30-60 versus >60 mL min −1 1.73 m −2 ) is presented in Table VI in the Data Supplement. GFR was found to affect the adjusted association between IT DM and 1-year mortality. Compared with no DM, IT DM showed an increased risk of adjusted 1-year mortality in patients with GFR >60 mL min − 
Discussion
The most important conclusion of our study, conducted in the world's largest TAVR registry, is that DM does not confer a significant incremental short-term risk factor at TAVR, but does confer significant longer-term risk. This increment in risk is greatest in IT diabetics. The major findings of this study are as follows: (1) at 1 year of follow-up, DM was associated with increased mortality even after adjustment for multiple baseline and procedural characteristics; (2) among diabetics, IT diabetics had increased 1-year mortality, compared with non-IT diabetics; (3) increased 1-year mortality in diabetics was driven mainly by increased mortality among patients with IT DM; and (4) 1-year heart failure readmission, MI, and new dialysis rates were higher among diabetic patients with IT DM patients having the highest risk for these adverse outcomes; (5) DM is not associated with increased short-term mortality after TAVR. DM has reached epidemic proportions worldwide, and its prevalence is rising. 22 It adversely affects morbidity and mortality for all types of cardiovascular disease including coronary artery disease, heart failure, and stroke. 8, [23] [24] [25] It is also adversely influence procedural outcomes after percutaneous and surgical procedures (eg, percutaneous coronary intervention and coronary artery bypass graft surgery). 26, 27 In patients with AS, DM is associated with accelerated valvular disease progression, increased hypertrophic remodeling, and reduced left ventricular systolic and diastolic function. [28] [29] [30] Moreover, it has been shown that DM is associated with significantly worse outcomes after surgical aortic valve replacement. 9, 31 Increased inflammation and oxidative stress and impaired left ventricular mass regression in diabetic patients are among the contributing factors suggested to explain the adverse effect of diabetic status on cardiac surgery outcomes. 16, [32] [33] [34] There have been limited number of relatively small studies that examined the short-and longer-term effects of DM on the clinical outcomes after TAVR, and the findings of these studies are contradictory. [10] [11] [12] [13] [14] [15] [16] [35] [36] [37] [38] [39] Assessment of predictors of increased short-and long-term mortality and complications from TAVR databases, registries, and clinical trials has suggested a link between DM and adverse clinical outcomes after TAVR.
We found an increased 1-year mortality in patients with DM compared with patients without DM even after adjusting for 41 baseline clinical, echocardiographic, and procedural variables (adjusted HR, 1.30; 95% CI, 1.13-1.49; P<0.001). Several other small previous registries reported similar res ults, 11,14,15,35,38 whereas other registries may have lacked the 
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statistical power to detect such an influence. 13, 36, 37 The prior uncertainty about the influence of DM on TAVR risk may in part reflect the counterintuitive results of the PARTNER trial, in which DM seemed to confer reduced risk in the TAVR arm (1-year mortality: 18.0% versus 27.8% in patients with and without DM, respectively). 16 Although this result remains unexplained, suggested potential explanations are the small sample size and selection bias before randomization, and the lack of multivariable analysis. The results of our present study contradict the possibility of such diabetic protective effect.
Only 4 previous studies have directly evaluated the relation between the clinical outcomes after TAVR and diabetic status, including subdivision to insulin and non-IT DM. 10, 15, 36, 37 Two of these studies have supported our findings by demonstrating that IT DM, but not non-IT DM, is independently associated with death at midterm follow-up. 10, 15 Multiple factors may account for the mechanisms linking IT DM to increased midterm mortality after TAVR. Diabetic patients treated with insulin are at a more advanced stage of the disease that is associated with increased mortality and multiple complications. Patients with longer duration and greater severity of DM also have higher prevalence of cardiovascular disease that is associated with higher cardiovascular mortality. 8, 24 Increased rate of comorbidities and their severity are probably the dominant factor influencing midterm mortality after TAVR among our cohort. Interesting insights into the mechanisms of increased midterm mortality among DM patients (mainly IT) can be observed from the findings of increased 1-year heart failure readmission, MI, and new dialysis among patients with DM and the higher risk for these adverse events among IT patients (Table 4 ; Figure 2 ).
Heart failure readmission rate was higher among IT and non-IT DM compared with patients with no DM (Figure 2 ). As expected, baseline left ventricular ejection fraction was lower among patients in both subgroups of DM versus nondiabetics (Table 1 ). In patients with severe AS, DM contributes to an additive adverse effect on LV remodeling and to both systolic and diastolic dysfunctions, mediated by increased hypertrophic remodeling and increased interstitial fibrosis. 28, 29 It has also been shown recently that DM impairs left ventricular mass regression and reverse remodeling after both TAVR and surgical valve replacement. 34 DM may accelerate and alter the pathophysiological process of AS, therefore, worsening postprocedural outcomes.
In-hospital MI rates were similar between groups (Table 2 ), yet 1-year MI rates were higher among diabetics (Table 4) . Several mechanisms may contribute to increased risk of MI in diabetic patients. Coronary atheroma of 
diabetics is more vulnerable to ulceration and rupture as they contain more macrophages and lipids. 40 Diabetic patients also have increased platelet activation and endothelial dysfunction, and they are more likely to have other risk factors which lead to rapid progression of atherosclerosis and higher tendency for unstable plaques to result in cardiac events and mortality. 41, 42 We also found increased risk of in-hospital acute kidney injury stage 3 and increase in the need for new dialysis at 1 year among diabetics (Tables 2 and 4 ; Figure 2 ). Patients with DM in the present cohort had lower GFR compared with nondiabetics, and both low GFR and baseline dialysis were found to independently influence 1-year mortality among diabetics ( Figure 3 ). Postprocedural acute kidney injury stage 3 was previously found to be a strong predictor of 1-year mortality after TAVR, 39 and DM is a strong predisposing factor for such injury. 43 Renal disease is an important contributor of death among patients with DM. 44 The results of present study emphasize the importance of meticulous kidney function assessment for DM patients after TAVR, with an effort to prevent and treat kidney injury during the initial hospitalization and during ambulatory follow-ups. Minimizing contrast usage during the procedure can potentially be beneficial, although it has not yet been proven in clinical studies for diabetic patients undergoing TAVR.
Whereas several previous studies demonstrated that DM is associated with increased short-term mortality after TAVR, 12, 13 other studies did not found such association. 11, 14, 15 Nonetheless, all these studies were relatively small. In the present study, we did not find an increase in 30-day mortality in patients with DM (adjusted HR for DM patients, 0.94; P=0.083). In-hospital mortality among 17 849 diabetic patients who underwent TAVR was even slightly lower compared to patients without DM (Table 2 ). These findings are reassuring, and contradictions to previous studies may be explained by the facts that vascular and bleeding complications were significantly more common in previous years when device profile and vascular access sheaths were larger. An association between major vascular and bleeding complications and IT DM has been demonstrated in the past. 45, 46 Minimizing these complications in contemporary clinical practice (Table 2 ) and reduced utilization of alternative access in recent years may also contribute to decreased rates and severity of systemic inflammatory response syndrome after TAVR, resulting in reduced short-term mortality after this procedure. 47 DM is included in both the STS risk score and the revised EuroScore II as a poor prognostic predictor after cardiac operation. 48, 49 Importantly, the results of the present study support exclusion of DM from future TAVR-specific short-term risk scores.
Study Limitations
This present analysis should be interpreted in light of several important potential limitations. The TVT Registry is a nonrandomized database that only includes information on patients receiving commercially approved devices. As several newer TAVR devices are currently under investigation in the United States, our data thus do not represent an allcomers population or the most recent iterations of transcatheter devices. Furthermore, many patients (31.1%; 14 824 of 47 643) could not be included in long-term outcome analysis because of inability to link with the CMS. Compared with patients without CMS linkage, patients with CMS linkage were more likely to be females; to be older; to have prior transient ischemic attack, hypertension, prior pacemaker, and atrial fibrillation/flutter; to have lower body mass index; and to have higher left ventricular ejection fraction and STS risk score. They were less likely to have prior cardiac surgery, baseline renal failure, and to be on dialysis before the procedure. It is unclear how including these patients without CMS linkage would have altered our results. Another potential limitation is that glycemic control and duration of DM prior TAVR were not systematically collected and, therefore, were not available for analysis. Nonetheless, the present study still represents the largest study of diabetics who have undergone TAVR and provides much-needed data to describe the outcomes of these high-risk patients. The moderate increase in 1-year mortality should not influence patient selection for TAVR, yet it should highlight the importance of meticulous follow-up for this group. Prospective and longer follow-up studies are needed to evaluate more comprehensively the prognostic value of diabetic status as a predictor of clinical outcomes after TAVR. 
Conclusions
In current US clinical practice, 1-year mortality is increased in diabetics after TAVR and this is driven mainly by increased mortality among patients with IT DM. One-year heart failure readmission, MI, and new dialysis rates were higher among diabetics with IT DM patients having the highest risk for these adverse events. DM is not associated with increased risk of short-term mortality or major complications except for acute kidney injury. Our data establish the magnitude of short-and long-term risk conferred by DM and the incremental risk conferred by insulin dependency in the performance of TAVR. Aggressive cardiovascular risk factor modification and guideline directed glycemic control and meticulous follow-up of renal function should be considered for IT DM patients who undergo TAVR.
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